Abstract
The purpose of our study was to evaluate the outcome of 78 consecutive patients with acute nonlymphocytic leukemia (ANLL) referred to our hospital from 1981 to 1987. They were treated with conventional remission-induction therapy consisting of 6-thioguanine, cytarabine, and daunorubicin (TAD) [1], and the characteristics of the patients which could be associated with remission failure or relapse were analyzed [2–5].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
